메뉴 건너뛰기




Volumn 139, Issue 3, 2013, Pages 789-800

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

Author keywords

Breast cancer; Cardiac toxicity; Efficacy; Genotyping; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

EID: 84879799660     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2587-x     Document Type: Article
Times cited : (58)

References (43)
  • 2
    • 22344446208 scopus 로고    scopus 로고
    • Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
    • 15911866 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D
    • Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265-4274
    • (2005) J Clin Oncol , vol.23 , pp. 4265-4274
    • Marty, M.1    Cognetti, F.2    Maraninchi, D.3    Snyder, R.4    Mauriac, L.5    Tubiana-Hulin, M.6    Chan, S.7    Grimes, D.8    Anton, A.9    Lluch, A.10    Kennedy, J.11    O'Byrne, K.12    Conte, P.13    Green, M.14    Ward, C.15    Mayne, K.16    Extra, J.M.17
  • 5
    • 80052728749 scopus 로고    scopus 로고
    • Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31
    • 21768458 10.1200/JCO.2011.35.0868 1:CAS:528:DC%2BC3MXhtlWisLbN
    • Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373
    • (2011) J Clin Oncol , vol.29 , pp. 3366-3373
    • Perez, E.A.1    Romond, E.H.2    Suman, V.J.3    Jeong, J.H.4    Davidson, N.E.5    Geyer, Jr.C.E.6    Martino, S.7    Mamounas, E.P.8    Kaufman, P.A.9    Wolmark, N.10
  • 8
    • 33846297680 scopus 로고    scopus 로고
    • Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
    • 17200359 10.1158/1078-0432.CCR-06-1345 1:CAS:528:DC%2BD2sXotlSq
    • Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233
    • (2007) Clin Cancer Res , vol.13 , pp. 228-233
    • Buzdar, A.U.1    Valero, V.2    Ibrahim, N.K.3    Francis, D.4    Broglio, K.R.5    Theriault, R.L.6    Pusztai, L.7    Green, M.C.8    Singletary, S.E.9    Hunt, K.K.10    Sahin, A.A.11    Esteva, F.12    Symmans, W.F.13    Ewer, M.S.14    Buchholz, T.A.15    Hortobagyi, G.N.16
  • 10
    • 77955653073 scopus 로고    scopus 로고
    • A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients
    • 20480225 10.1007/s10549-010-0939-3 1:CAS:528:DC%2BC3cXnsFymu7s%3D
    • Pierga JY, Delaloge S, Espie M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretiere JM, Spielmann M, Savignoni A, Marty M (2010) A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 122:429-437
    • (2010) Breast Cancer Res Treat , vol.122 , pp. 429-437
    • Pierga, J.Y.1    Delaloge, S.2    Espie, M.3    Brain, E.4    Sigal-Zafrani, B.5    Mathieu, M.C.6    Bertheau, P.7    Guinebretiere, J.M.8    Spielmann, M.9    Savignoni, A.10    Marty, M.11
  • 12
    • 34548152541 scopus 로고    scopus 로고
    • Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
    • 17687157 10.1200/JCO.2007.11.0106 1:CAS:528:DC%2BD2sXhtVajsb3M
    • Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525-3533
    • (2007) J Clin Oncol , vol.25 , pp. 3525-3533
    • Telli, M.L.1    Hunt, S.A.2    Carlson, R.W.3    Guardino, A.E.4
  • 13
    • 65349101151 scopus 로고    scopus 로고
    • Ligand-independent HER2/HER3/PI3 K complex is disrupted by trastuzumab and is effectively inhibited by the PI3 K inhibitor GDC-0941
    • 19411071 10.1016/j.ccr.2009.03.020 1:CAS:528:DC%2BD1MXmvVGitrg%3D
    • Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX (2009) Ligand-independent HER2/HER3/PI3 K complex is disrupted by trastuzumab and is effectively inhibited by the PI3 K inhibitor GDC-0941. Cancer Cell 15:429-440
    • (2009) Cancer Cell , vol.15 , pp. 429-440
    • Junttila, T.T.1    Akita, R.W.2    Parsons, K.3    Fields, C.4    Lewis Phillips, G.D.5    Friedman, L.S.6    Sampath, D.7    Sliwkowski, M.X.8
  • 15
    • 0642373290 scopus 로고    scopus 로고
    • Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
    • 12975461 10.1200/JCO.2003.05.013 1:CAS:528:DC%2BD2cXpsVajsb8%3D
    • Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947
    • (2003) J Clin Oncol , vol.21 , Issue.21 , pp. 3940-3947
    • Weng, W.K.1    Levy, R.2
  • 16
    • 78751524881 scopus 로고    scopus 로고
    • Interindividual variability of response to rituximab: From biological origins to individualized therapies
    • 21208903 10.1158/1078-0432.CCR-10-1292 1:CAS:528:DC%2BC3MXhtVemsg%3D%3D
    • Cartron G, Trappe RU, Solal-Céligny P, Hallek M (2011) Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 17:19-30
    • (2011) Clin Cancer Res , vol.17 , pp. 19-30
    • Cartron, G.1    Trappe, R.U.2    Solal-Céligny, P.3    Hallek, M.4
  • 17
    • 0036464719 scopus 로고    scopus 로고
    • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    • 11806974 10.1182/blood.V99.3.754 1:CAS:528:DC%2BD38XhtVals7k%3D
    • Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
    • (2002) Blood , vol.99 , pp. 754-758
    • Cartron, G.1    Dacheux, L.2    Salles, G.3    Solal-Celigny, P.4    Bardos, P.5    Colombat, P.6    Watier, H.7
  • 18
    • 34548179576 scopus 로고    scopus 로고
    • Role of the HER2 [Ile655 Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
    • 17693647 10.1093/annonc/mdm181 1:STN:280:DC%2BD2svnsFSjtQ%3D%3D
    • Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, Hofman P, Ferrero JM, Pages G, Milano G (2007) Role of the HER2 [Ile655 Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 18:1335-1341
    • (2007) Ann Oncol , vol.18 , pp. 1335-1341
    • Beauclair, S.1    Formento, P.2    Fischel, J.L.3    Lescaut, W.4    Largillier, R.5    Chamorey, E.6    Hofman, P.7    Ferrero, J.M.8    Pages, G.9    Milano, G.10
  • 19
    • 42949157368 scopus 로고    scopus 로고
    • Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
    • 18347005 10.1200/JCO.2007.14.8957 1:CAS:528:DC%2BD1cXmsFemsLg%3D
    • Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796
    • (2008) J Clin Oncol , vol.26 , pp. 1789-1796
    • Musolino, A.1    Naldi, N.2    Bortesi, B.3    Pezzuolo, D.4    Capelletti, M.5    Missale, G.6    Laccabue, D.7    Zerbini, A.8    Camisa, R.9    Bisagni, G.10    Neri, T.M.11    Ardizzoni, A.12
  • 22
    • 84866646922 scopus 로고    scopus 로고
    • Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
    • 23028798 10.1371/journal.pone.0045127 1:CAS:528:DC%2BC38XhsVaktr7M
    • Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J (2012) Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. PLoS One 7:e45127
    • (2012) PLoS One , vol.7 , pp. 45127
    • Jung, M.1    Koo, J.S.2    Moon, Y.W.3    Park, B.W.4    Kim, S.I.5    Park, S.6    Lee, S.H.7    Hong, S.8    Rha, S.Y.9    Chung, H.C.10    Kim, J.H.11    Sohn, J.12
  • 23
    • 84865054217 scopus 로고    scopus 로고
    • ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy
    • 22906996 10.1159/000341359 1:CAS:528:DC%2BC38Xht12nu7rE
    • Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Han SW, Jeon YK, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ (2012) ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology 83:218-227
    • (2012) Oncology , vol.83 , pp. 218-227
    • Kim, J.W.1    Kim, J.H.2    Im, S.A.3    Kim, Y.J.4    Han, H.S.5    Kim, J.S.6    Han, S.W.7    Jeon, Y.K.8    Oh, D.Y.9    Han, W.10    Kim, T.Y.11    Park, I.A.12    Noh, D.Y.13    Bang, Y.J.14
  • 26
    • 81555216077 scopus 로고    scopus 로고
    • Gene expression profiling in breast cancer: Classification, prognostication, and prediction
    • 22098854 10.1016/S0140-6736(11)61539-0 1:CAS:528:DC%2BC3MXhsVyrs7nE
    • Reis-Filho JS, Pusztai L (2011) Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378:1812-1823
    • (2011) Lancet , vol.378 , pp. 1812-1823
    • Reis-Filho, J.S.1    Pusztai, L.2
  • 27
    • 60849097255 scopus 로고    scopus 로고
    • Gene-expression signatures in breast cancer
    • 19228622 10.1056/NEJMra0801289 1:CAS:528:DC%2BD1MXitFWqs70%3D
    • Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790-800
    • (2009) N Engl J Med , vol.360 , pp. 790-800
    • Sotiriou, C.1    Pusztai, L.2
  • 28
    • 0022600388 scopus 로고
    • The neu oncogene encodes an epidermal growth factor receptor-related protein
    • 3945311 10.1038/319226a0 1:CAS:528:DyaL28XhtVensLk%3D
    • Bargmann CI, Hung MC, Weinberg RA (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230
    • (1986) Nature , vol.319 , pp. 226-230
    • Bargmann, C.I.1    Hung, M.C.2    Weinberg, R.A.3
  • 29
    • 0032078876 scopus 로고    scopus 로고
    • ERBB2 oncogene in human breast cancer and its clinical significance
    • 9797688 10.1016/S0959-8049(97)10157-5 1:STN:280:DyaK1M%2FhsVChsA%3D%3D
    • Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808
    • (1998) Eur J Cancer , vol.34 , pp. 791-808
    • Revillion, F.1    Bonneterre, J.2    Peyrat, J.P.3
  • 31
    • 81055140610 scopus 로고    scopus 로고
    • Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: A systematic review and meta-analysis
    • 21474413 10.1016/j.canep.2011.01.007 1:CAS:528:DC%2BC3MXhsVOks73P
    • Dahabreh IJ, Murray S (2011) Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 35:503-509
    • (2011) Cancer Epidemiol , vol.35 , pp. 503-509
    • Dahabreh, I.J.1    Murray, S.2
  • 32
    • 78651076978 scopus 로고    scopus 로고
    • Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: Meta-analysis of 22 studies involving 19,341 subjects
    • 20524057 10.1007/s10549-010-0965-1 1:CAS:528:DC%2BC3cXhsFWgtL%2FO
    • Ma Y, Yang J, Zhang P, Liu Z, Yang Z, Qin H (2011) Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects. Breast Cancer Res Treat 125:237-241
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 237-241
    • Ma, Y.1    Yang, J.2    Zhang, P.3    Liu, Z.4    Yang, Z.5    Qin, H.6
  • 33
    • 0034163421 scopus 로고    scopus 로고
    • Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk
    • 10699071 10.1093/jnci/92.5.412 1:CAS:528:DC%2BD3cXhvFGhu70%3D
    • Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412-417
    • (2000) J Natl Cancer Inst , vol.92 , pp. 412-417
    • Xie, D.1    Shu, X.O.2    Deng, Z.3    Wen, W.Q.4    Creek, K.E.5    Dai, Q.6    Gao, Y.T.7    Jin, F.8    Zheng, W.9
  • 34
    • 18744378545 scopus 로고    scopus 로고
    • A putative molecular-activation switch in the transmembrane domain of erbB2
    • 12461170 10.1073/pnas.252640799 1:CAS:528:DC%2BD38Xps1egurk%3D
    • Fleishman SJ, Schlessinger J, Ben-Tal N (2002) A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 99:15937-15940
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 15937-15940
    • Fleishman, S.J.1    Schlessinger, J.2    Ben-Tal, N.3
  • 35
    • 84865453635 scopus 로고    scopus 로고
    • Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody
    • 22794164 10.1021/ac301426h 1:CAS:528:DC%2BC38XhtVSqtrvN
    • Zhang T, Zhang J, Hewitt D, Tran B, Gao X, Qiu ZJ, Tejada M, Gazzano-Santoro H, Kao YH (2012) Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody. Anal Chem 84:7112-7123
    • (2012) Anal Chem , vol.84 , pp. 7112-7123
    • Zhang, T.1    Zhang, J.2    Hewitt, D.3    Tran, B.4    Gao, X.5    Qiu, Z.J.6    Tejada, M.7    Gazzano-Santoro, H.8    Kao, Y.H.9
  • 36
    • 0034076307 scopus 로고    scopus 로고
    • Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
    • 10742152 10.1038/74704 1:CAS:528:DC%2BD3cXisVOru7Y%3D
    • Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446
    • (2000) Nat Med , vol.6 , pp. 443-446
    • Clynes, R.A.1    Towers, T.L.2    Presta, L.G.3    Ravetch, J.V.4
  • 37
    • 0034772498 scopus 로고    scopus 로고
    • Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells
    • 11592078 10.1002/1521-4141(2001010)31:10<3016: AID-IMMU3016>3.0. CO;2-J 1:CAS:528:DC%2BD3MXnvFSgtb4%3D
    • Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31:3016-3025
    • (2001) Eur J Immunol , vol.31 , pp. 3016-3025
    • Carson, W.E.1    Parihar, R.2    Lindemann, M.J.3    Personeni, N.4    Dierksheide, J.5    Meropol, N.J.6    Baselga, J.7    Caligiuri, M.A.8
  • 38
    • 0030611089 scopus 로고    scopus 로고
    • A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease
    • 9276722 10.1172/JCI119616 1:CAS:528:DyaK2sXlvFOgs7k%3D
    • Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP (1997) A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100:1059-1070
    • (1997) J Clin Invest , vol.100 , pp. 1059-1070
    • Wu, J.1    Edberg, J.C.2    Redecha, P.B.3    Bansal, V.4    Guyre, P.M.5    Coleman, K.6    Salmon, J.E.7    Kimberly, R.P.8
  • 39
    • 27144497346 scopus 로고    scopus 로고
    • Singleagent rituximab in patients with follicular ormantle cell lymphoma: Clinical and biological factors that are predictive of response and event free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK)
    • 16030029 10.1093/annonc/mdi320 1:STN:280:DC%2BD2MvpvFKitA%3D%3D
    • Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF (2005) Singleagent rituximab in patients with follicular ormantle cell lymphoma: clinical and biological factors that are predictive of response and event free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16:1675-1682
    • (2005) Ann Oncol , vol.16 , pp. 1675-1682
    • Ghielmini, M.1    Rufibach, K.2    Salles, G.3    Leoncini-Franscini, L.4    Léger-Falandry, C.5    Cogliatti, S.6    Fey, M.7    Martinelli, G.8    Stahel, R.9    Lohri, A.10    Ketterer, N.11    Wernli, M.12    Cerny, T.13    Schmitz, S.F.14
  • 40
    • 84862123411 scopus 로고    scopus 로고
    • Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
    • 22271896 10.3324/haematol.2011.050419
    • Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM (2012) Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 97:937-994
    • (2012) Haematologica , vol.97 , pp. 937-994
    • Goldman, B.H.1    Braziel, R.M.2    Fisher, R.I.3    Leblanc, M.4    Maloney, D.G.5    Press, O.W.6    Miller, T.P.7    Rimsza, L.M.8
  • 41
    • 34548509226 scopus 로고    scopus 로고
    • FCGR2A and FCGR3A polymorp hisms associated with clinical outcome of epiderman growth factor receptor expressing metastatic colorectalpatients treated with single agent cetuximab
    • 10.1200/JCO.2006.08.8021
    • Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ (2007) FCGR2A and FCGR3A polymorp hisms associated with clinical outcome of epiderman growth factor receptor expressing metastatic colorectalpatients treated with single agent cetuximab. J Clin Oncol 24:3712-3718
    • (2007) J Clin Oncol , vol.24 , pp. 3712-3718
    • Zhang, W.1    Gordon, M.2    Schultheis, A.M.3    Yang, D.Y.4    Nagashima, F.5    Azuma, M.6    Chang, H.M.7    Borucka8    Lurje, G.9    Sherrod, A.E.10    Iqbal, S.11    Groshen, S.12    Lenz, H.J.13
  • 43
    • 56749096598 scopus 로고    scopus 로고
    • Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies
    • 18955438 10.1200/JCO.2008.19.4118 author reply 5491- 5482
    • Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M (2008) Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 26:5489-5491 author reply 5491- 5482
    • (2008) J Clin Oncol , vol.26 , pp. 5489-5491
    • Lejeune, J.1    Thibault, G.2    Ternant, D.3    Cartron, G.4    Watier, H.5    Ohresser, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.